Prophylaxis With Pi3 Kinase Inhibitors

Prophylaxis With Pi3 Kinase Inhibitors

imedex

1 year
82 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Jennifer Brown, M.D., Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and an Associate Professor of Medicine at Harvard Medical School in Boston, Massachusetts discusses Prophylaxis With Pi3 Kinase Inhibitors at Lymphoma & Myeloma on October 18, 2018.
Up Next Autoplay
Phase III Lumoxiti #ASH19
Phase III Lumoxiti #ASH19
Category: Chronic Lymphocytic Leukemia
44 Views
ash 1 month
Sickle Cell Research #ASH19
Sickle Cell Research #ASH19
Category: Chronic Lymphocytic Leukemia
6 Views
ash 1 month
Transcend CLL 004 Update #ASH19 @cityofhope
Transcend CLL 004 Update #ASH19 @cityofhope
Category: Chronic Lymphocytic Leukemia
8 Views
ash 1 month
Phase III ELEVATE TN Trial #ASH19 #ASH @TheUSONetwork
Phase III ELEVATE TN Trial #ASH19 #ASH @TheUSONetwork
Category: Chronic Lymphocytic Leukemia
19 Views
ash 1 month
CALQUENCE Significantly Prolonged the Time Patients Lived Without Disease Progression or Death in Previously Untreated Chronic Lymphocytic Leukemia
CALQUENCE Significantly Prolonged the Time Patients Lived Without Disease Progression or Death in Previously Untreated Chronic Lymphocytic Leukemia
Category: Chronic Lymphocytic Leukemia
33 Views
Cancer-News 1 month
MURANO Trial #ASH19 @abbvie
MURANO Trial #ASH19 @abbvie
Category: Chronic Lymphocytic Leukemia
56 Views
ash 1 month
Phase I Study of Duvelisib in CLL/SLL #ASH19 #ASH @DanaFarber
Phase I Study of Duvelisib in CLL/SLL #ASH19 #ASH @DanaFarber
Category: Chronic Lymphocytic Leukemia
20 Views
ash 1 month
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Category: Chronic Lymphocytic Leukemia
5 Views
ash 1 month
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL #ASH19 #ASH
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL #ASH19 #ASH
Category: Chronic Lymphocytic Leukemia
3 Views
ash 1 month
4-Year Update of the Echelon-1 Study #ASH19 #ASH @TakedaOncology
4-Year Update of the Echelon-1 Study #ASH19 #ASH @TakedaOncology
Category: Chronic Lymphocytic Leukemia
22 Views
ash 1 month